On April 24, 2025 PharmaMar (MSE:PHM) a global leader in the research, development, and commercialization of marine-derived oncology therapies, reported it will be present at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), that will take place between the 30th of May and the 3rd of June in Chicago, U.S.A (Press release, PharmaMar, APR 24, 2025, View Source [SID1234652110]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Included among the key presentations an oral abstract of the Phase 3 IMforte trial. "Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) underscore potential of first line maintenance therapy for extensive stage small cell lung cancer (ES-SCLC), a much-needed advancement for patients", commented Javier Jiménez, Chief Medical Officer of PharmaMar.
The Company also will host an investor webcast on June 12th to review Phase 3 IMforte data being presented at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting. The webcast will include commentaries from leading European experts in small cell lung cancer. The webcast can be accessed at View Source Additional details will be provided prior to the webcast.
The full list of PharmaMar or partner-supported presentations at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting are:
PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase 3 IMforte trial Luis G. Paz-Ares, MD, PhD TYPE: Oral Abstract SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8006 DATE: June 2nd, 2025 (03:00 PM- 06: PM CDT)
Safety and Efficacy of Lurbinectedin Plus Atezolizumab as Second-Line Treatment for Advanced Small-Cell Lung Cancer: Results of the 2SMALL Phase 1/2 Study (NCT04253145) Santiago Ponce, MD, PhD TYPE: Rapid Oral Abstract SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8013 DATE: June 1st, 2025 (04:30 PM- 06:00 PM CDT)
Evaluation of combination of lurbinectedin plus atezolizumab in humanized mouse model Antonio Calles, MD, PHD TYPE: e-poster ABSTRACT: e14614 DATE: May 22nd, 2025 (05:00 PM CDT)